Home | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Contact | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Careers | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE ...
Mar 3, 2026 · Harrow believes the planned Phase 3 trial represents an important opportunity to further strengthen the clinical and commercial profile of TRIESENCE. The study is designed to generate …
Products | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
0001493152-23-008718 | 10-K | Harrow, Inc.
Dec 31, 2022 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Stock Quote & Chart - Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic ...
Jan 11, 2024 · Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry …
Harrow Announces Third Quarter 2025 Financial Results
Sep 30, 2025 · NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results …
0001493152-26-004635 | 8-K | Harrow, Inc.
Jan 30, 2026 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.